Images |
Sources |
Experiment + Assay |
Phenotypes |
Human Diseases |
|
Fig. 2 ST
Pera EM et al. (2024)
|
Xla Wt + serpine2 MO
NF26 (in situ hybridization)
|
|
|
|
Fig.6.S1.H
Chen M et al. (2020)
|
Xla Wt + tmem79 MO
NF16 (in situ hybridization)
|
|
|
|
Fig. 4 C lane 3
Lichtig H et al. (2020)
|
Xla + asxl3 MO
NF16 (RT-PCR)
|
|
|
|
Fig. 2 c
Harata A et al. (2019)
|
Xla Wt + p2ry4 TALEN
NF13 (in situ hybridization)
|
|
|
|
Fig. 2 f
Harata A et al. (2019)
|
Xla Wt + p2ry4 TALEN
NF27 (in situ hybridization)
|
|
|
|
Fig 2. b
Melchionda M et al. (2016)
|
Xla Wt + CAX MO
NF23-24 (in situ hybridization)
|
|
|
|
Fig 2. b
Melchionda M et al. (2016)
|
Xla Wt + CAX MO
NF23-24 (in situ hybridization)
|
|
|
|
fig.2.g
Julier A et al. (2012)
|
Xla Wt + pou5f3.2
NF11-11.5 (in situ hybridization)
|
|
|
|
fig.2.l
Julier A et al. (2012)
|
Xla Wt + pou5f3.2
NF11-11.5 (in situ hybridization)
|
|
|
|
fig.7.a
Agüero TH et al. (2012)
|
Xla Wt + Cyclopamine
NF13 (in situ hybridization)
|
|
|